TCIM
ADMS

TIAA CREF Investment Management’s Adamas Pharmaceuticals ADMS Stock Holding History

TIAA CREF Investment Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$296K Hold
41,636
– – ﹤0.01% 2779
2018
Q4 		$356K Sell
41,636
-620
-1% -$8.06K ﹤0.01% 2710
2018
Q3 		$846K Sell
42,256
-3,718
-8% -$87.3K ﹤0.01% 2502
2018
Q2 		$1.19M Buy
45,974
+3,886
+9% +$108K ﹤0.01% 2421
2018
Q1 		$1.01M Buy
42,088
+3,939
+10% +$124K ﹤0.01% 2443
2017
Q4 		$1.29M Sell
38,149
-24,502
-39% -$684K ﹤0.01% 2340
2017
Q3 		$1.33M Buy
62,651
+17,592
+39% +$322K ﹤0.01% 2380
2017
Q2 		$788K Sell
45,059
-935
-2% -$15.5K ﹤0.01% 2657
2017
Q1 		$805K Sell
45,994
-1,872
-4% -$31.9K ﹤0.01% 2620
2016
Q4 		$809K Sell
47,866
-6,170
-11% -$95.4K ﹤0.01% 2651
2016
Q3 		$887 Sell
54,036
-760
-1% -$11.6K ﹤0.01% 2604
2016
Q2 		$830K Buy
54,796
+18,499
+51% +$305K ﹤0.01% 2614
2016
Q1 		$525K Buy
36,297
+1,598
+5% +$26.9K ﹤0.01% 2770
2015
Q4 		$983K Hold
34,699
– – ﹤0.01% 2593
2015
Q3 		$581K Buy
34,699
+12,633
+57% +$287K ﹤0.01% 2838
2015
Q2 		$579K Buy
22,066
+12,569
+132% +$244K ﹤0.01% 2921
2015
Q1 		$166K Hold
9,497
– – ﹤0.01% 3071
2014
Q4 		$165K Sell
9,497
-78
-0.8% -$1.18K ﹤0.01% 3106
2014
Q3 		$178K Buy
9,575
+1,240
+15% +$21.3K ﹤0.01% 3091
2014
Q2 		$152K Buy
+8,335
New +$149K ﹤0.01% 3085

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

TIAA CREF Investment Management's ADMS Position: Q1 2019 in Review

TIAA CREF Investment Management held its Adamas Pharmaceuticals (ADMS) position steady in Q1 2019 at 41,636 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #2779.

TIAA CREF Investment Management first reported a position in ADMS in Q2 2014 and has held it in 20 quarters since. The position peaked at $1.33M in Q3 2017. 99 funds tracked by Wall St. Rank hold ADMS as of Q1 2019.

  • TIAA CREF Investment Management held 41,636 shares of Adamas Pharmaceuticals worth $296K as of Q1 2019.
  • TIAA CREF Investment Management left its Adamas Pharmaceuticals share count unchanged in Q1 2019.
  • Adamas Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2779 holding.
  • TIAA CREF Investment Management first reported a position in Adamas Pharmaceuticals in Q2 2014 and has held it in 20 quarters since.
  • TIAA CREF Investment Management's Adamas Pharmaceuticals position peaked at $1.33M in Q3 2017.
  • 99 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.